CN101888834A - 口服分散片 - Google Patents
口服分散片 Download PDFInfo
- Publication number
- CN101888834A CN101888834A CN2008801194609A CN200880119460A CN101888834A CN 101888834 A CN101888834 A CN 101888834A CN 2008801194609 A CN2008801194609 A CN 2008801194609A CN 200880119460 A CN200880119460 A CN 200880119460A CN 101888834 A CN101888834 A CN 101888834A
- Authority
- CN
- China
- Prior art keywords
- tablet
- oral
- cellulose
- agent
- microcrystalline cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
物质 | 量[mg/片] | 质量[%] |
活性物质*) | 50.25 | 30.15% |
Prosolv(SMMC 90) | 101.00 | 60.61% |
L-HPC类型B1 | 13.30 | 7.98% |
十二烷基硫酸钠 | 0.42 | 0.25% |
NaCl | 0.50 | 0.30% |
糖精钠 | 0.17 | 0.10% |
硬脂富马酸钠 | 1.00 | 0.60% |
物质 | 量[mg/片] | 质量[%] |
片剂 | 166.64 | 100.00% |
物质 | 量[mg/片] | 质量[%] |
活性物质*) | 50.25 | 30.15% |
Prosolv(SMMC 90) | 75.00 | 45.01% |
Avicel PH200 | 26.08 | 15.65% |
L-HPC类型B1 | 13.30 | 7.98% |
十二烷基硫酸钠 | 0.42 | 0.25% |
NaCl | 0.50 | 0.30% |
糖精钠 | 0.09 | 0.05% |
硬脂富马酸钠 | 1.00 | 0.60% |
片剂 | 166.64 | 100.00% |
物质 | 量[mg/片] | 质量[%] |
活性物质*) | 50.25 | 30.21% |
Prosolv(SMMC 90) | 45.00 | 27.05% |
Avicel PH200 | 26.08 | 15.68% |
Arbocel P290 | 25.00 | 15.03% |
L-HPC类型B1 | 18.00 | 10.82% |
物质 | 量[mg/片] | 质量[%] |
十二烷基硫酸钠 | 0.42 | 0.25% |
NaCl | 0.50 | 0.30% |
糖精钠 | 0.09 | 0.05% |
硬脂富马酸钠 | 1.00 | 0.60% |
片剂 | 166.34 | 100.00% |
物质 | 量[mg/片] | 质量[%] |
活性物质*) | 50.25 | 30.21% |
Prosolv(SMMC 90) | 45.00 | 27.05% |
Arbocel 290 | 20.00 | 12.02% |
Kollidon CL | 49.08 | 29.51% |
十二烷基硫酸钠 | 0.42 | 0.25% |
NaCl | 0.50 | 0.30% |
糖精钠 | 0.09 | 0.05% |
硬脂富马酸钠 | 1.00 | 0.60% |
片剂 | 166.34 | 100.00% |
物质 | 量[mg/片] | 质量[%] |
活性物质*) | 50.25 | 30.21% |
物质 | 量[mg/片] | 质量[%] |
Prosolv(SMMC 90) | 45.00 | 27.05% |
Arbocel 290 | 30.00 | 18.04% |
Kollidon CL | 39.08 | 23.49% |
十二烷基硫酸钠 | 0.42 | 0.25% |
NaCl | 0.50 | 0.30% |
糖精钠 | 0.09 | 0.05% |
硬脂富马酸钠 | 1.00 | 0.60% |
片剂 | 166.34 | 100.00% |
物质 | 量[mg/片] | 质量[%] |
活性物质*) | 50.25 | 30.21% |
Prosolv(SMMC 90) | 45.00 | 27.05% |
Aqualon ECT10 | 38.00 | 22.84% |
Kollidon CL | 15.08 | 9.07% |
L-HPC类型B1 | 16.00 | 9.62% |
十二烷基硫酸钠 | 0.42 | 0.25% |
NaCl | 0.50 | 0.30% |
糖精钠 | 0.09 | 0.05% |
硬脂富马酸钠 | 1.00 | 0.60% |
物质 | 量[mg/片] | 质量[%] |
片剂 | 166.34 | 100.00% |
Claims (11)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07023802 | 2007-12-08 | ||
EP07023802.7 | 2007-12-08 | ||
PCT/EP2008/009968 WO2009071219A2 (en) | 2007-12-08 | 2008-11-25 | Oral dispersable tablet |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101888834A true CN101888834A (zh) | 2010-11-17 |
Family
ID=40631079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801194609A Pending CN101888834A (zh) | 2007-12-08 | 2008-11-25 | 口服分散片 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2231126A2 (zh) |
JP (2) | JP2011506279A (zh) |
KR (1) | KR20100096140A (zh) |
CN (1) | CN101888834A (zh) |
BR (1) | BRPI0820861A2 (zh) |
MX (1) | MX2010005175A (zh) |
RU (1) | RU2010128019A (zh) |
TW (1) | TW200938233A (zh) |
WO (1) | WO2009071219A2 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102600149A (zh) * | 2012-02-02 | 2012-07-25 | 西藏易明西雅生物医药科技有限公司 | 一种治疗糖尿病的药物组合物 |
CN103877041A (zh) * | 2014-03-14 | 2014-06-25 | 崔书豪 | 一种吡罗昔康分散片及其制备方法 |
CN105640954A (zh) * | 2016-02-04 | 2016-06-08 | 侯芳霖 | 一种治疗消化不良的西沙必利片剂 |
CN107334742A (zh) * | 2017-08-18 | 2017-11-10 | 山东力诺制药有限公司 | 一种盐酸氟西汀分散片及其制备方法 |
CN107595788A (zh) * | 2016-07-11 | 2018-01-19 | 武汉朗来科技发展有限公司 | 一种用于口服固体制剂的复合崩解剂体系及含有该复合崩解剂体系的口服固体制剂 |
CN109864971A (zh) * | 2019-04-08 | 2019-06-11 | 西安远大德天药业股份有限公司 | 一种拉莫三嗪固体分散体的颗粒剂及其制备方法 |
CN110840850A (zh) * | 2018-07-24 | 2020-02-28 | 烟台药物研究所 | 一种高生物利用度的塞来昔布冻干口崩片及其制备方法 |
CN111032020A (zh) * | 2017-09-28 | 2020-04-17 | 韩美药品株式会社 | 包括含埃索美拉唑及球形药学可接受盐的多单元球形片剂药物组合物及药物组合物制备方法 |
CN113262204A (zh) * | 2016-01-29 | 2021-08-17 | 株式会社Kit | 固体制剂、固体制剂的制备方法及析氢方法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5696050B2 (ja) * | 2009-09-08 | 2015-04-08 | 協和化学工業株式会社 | 制酸・緩下用錠剤 |
CN101797236B (zh) * | 2010-03-23 | 2012-05-23 | 西南大学 | 重酒石酸卡巴拉汀口腔崩解片及其制备方法 |
BR112012027303A2 (pt) * | 2010-04-27 | 2017-10-24 | Bayer Ip Gmbh | comprimido de desintegração oral contendo acarbose |
US20110300216A1 (en) * | 2010-06-03 | 2011-12-08 | First Eric R | Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives |
JP5750856B2 (ja) * | 2010-10-04 | 2015-07-22 | ライオン株式会社 | 固形医薬組成物及び医薬製剤 |
KR101237646B1 (ko) * | 2010-12-09 | 2013-03-04 | 주식회사 드림파마 | 생체이용률이 개선된 셀레콕시브 함유 고체 분산체, 이를 포함하는 약학 조성물 및 이의 제조방법 |
FR2968995B1 (fr) * | 2010-12-16 | 2013-03-22 | Sanofi Aventis | Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage |
FR2968992B1 (fr) * | 2010-12-16 | 2013-02-08 | Sanofi Aventis | Comprime pharmaceutique orodispersible a base de zolpidem |
TR201100150A2 (tr) * | 2011-01-06 | 2012-07-23 | Bi̇lgi̇ç Mahmut | Suda çözünür dozaj formları |
WO2013115741A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | Pharmaceutical compositions comprising alpha-glucosidase inhibitor |
EP3023109A4 (en) | 2013-07-19 | 2017-01-04 | Sanwa Kagaku Kenkyusho Co., Ltd | Orally disintegrating tablet |
WO2015007676A1 (en) * | 2013-07-19 | 2015-01-22 | Bayer Pharma Aktiengesellschaft | Super quick disintegrating tablet formula for api miglitol |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
WO2018037819A1 (ja) | 2016-08-23 | 2018-03-01 | 小林 光 | 配合物及びその製造方法、並びに水素供給方法 |
US11583483B2 (en) | 2016-08-23 | 2023-02-21 | Bosquet Silicon Corp. | Hydrogen supply material and production therefor, and hydrogen supply method |
CN114224855B (zh) * | 2021-12-01 | 2023-11-28 | 北京悦康科创医药科技股份有限公司 | 一种甲磺酸多沙唑嗪口含片及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19802700A1 (de) * | 1998-01-24 | 1999-07-29 | Bayer Ag | Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält |
EP1469829B1 (en) * | 2002-02-01 | 2016-01-27 | Bend Research, Inc | Immediate release dosage forms containing solid drug dispersions |
US20040265375A1 (en) * | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
CA2524806C (en) * | 2003-05-07 | 2011-07-12 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
US7230016B2 (en) * | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
US20070196477A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly dissolving tablets comprising low surface area calcium phosphates |
US20070196474A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly disintegrating low friability tablets comprising calcium carbonate |
GB0423103D0 (en) * | 2004-10-19 | 2004-11-17 | Boots Healthcare Int Ltd | Therapeutic agents |
-
2008
- 2008-11-25 WO PCT/EP2008/009968 patent/WO2009071219A2/en active Application Filing
- 2008-11-25 BR BRPI0820861-1A patent/BRPI0820861A2/pt not_active IP Right Cessation
- 2008-11-25 JP JP2010536354A patent/JP2011506279A/ja active Pending
- 2008-11-25 EP EP08856436A patent/EP2231126A2/en not_active Withdrawn
- 2008-11-25 MX MX2010005175A patent/MX2010005175A/es not_active Application Discontinuation
- 2008-11-25 CN CN2008801194609A patent/CN101888834A/zh active Pending
- 2008-11-25 RU RU2010128019/15A patent/RU2010128019A/ru not_active Application Discontinuation
- 2008-11-25 KR KR1020107012467A patent/KR20100096140A/ko not_active Application Discontinuation
- 2008-12-01 TW TW97146532A patent/TW200938233A/zh unknown
-
2014
- 2014-10-09 JP JP2014208122A patent/JP2015038123A/ja active Pending
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102600149A (zh) * | 2012-02-02 | 2012-07-25 | 西藏易明西雅生物医药科技有限公司 | 一种治疗糖尿病的药物组合物 |
CN103877041A (zh) * | 2014-03-14 | 2014-06-25 | 崔书豪 | 一种吡罗昔康分散片及其制备方法 |
CN103877041B (zh) * | 2014-03-14 | 2016-07-06 | 崔书豪 | 一种吡罗昔康分散片及其制备方法 |
CN113262204A (zh) * | 2016-01-29 | 2021-08-17 | 株式会社Kit | 固体制剂、固体制剂的制备方法及析氢方法 |
CN105640954B (zh) * | 2016-02-04 | 2019-03-05 | 青岛市海慈医疗集团 | 一种治疗消化不良的西沙必利片剂 |
CN105640954A (zh) * | 2016-02-04 | 2016-06-08 | 侯芳霖 | 一种治疗消化不良的西沙必利片剂 |
CN107595788A (zh) * | 2016-07-11 | 2018-01-19 | 武汉朗来科技发展有限公司 | 一种用于口服固体制剂的复合崩解剂体系及含有该复合崩解剂体系的口服固体制剂 |
CN107334742A (zh) * | 2017-08-18 | 2017-11-10 | 山东力诺制药有限公司 | 一种盐酸氟西汀分散片及其制备方法 |
CN107334742B (zh) * | 2017-08-18 | 2020-01-31 | 山东力诺制药有限公司 | 一种盐酸氟西汀分散片及其制备方法 |
CN111032020A (zh) * | 2017-09-28 | 2020-04-17 | 韩美药品株式会社 | 包括含埃索美拉唑及球形药学可接受盐的多单元球形片剂药物组合物及药物组合物制备方法 |
CN110840850A (zh) * | 2018-07-24 | 2020-02-28 | 烟台药物研究所 | 一种高生物利用度的塞来昔布冻干口崩片及其制备方法 |
CN109864971A (zh) * | 2019-04-08 | 2019-06-11 | 西安远大德天药业股份有限公司 | 一种拉莫三嗪固体分散体的颗粒剂及其制备方法 |
CN109864971B (zh) * | 2019-04-08 | 2021-12-17 | 西安远大德天药业股份有限公司 | 一种拉莫三嗪固体分散体的颗粒剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
TW200938233A (en) | 2009-09-16 |
BRPI0820861A2 (pt) | 2015-06-16 |
JP2011506279A (ja) | 2011-03-03 |
WO2009071219A3 (en) | 2009-09-11 |
EP2231126A2 (en) | 2010-09-29 |
WO2009071219A2 (en) | 2009-06-11 |
RU2010128019A (ru) | 2012-01-20 |
JP2015038123A (ja) | 2015-02-26 |
MX2010005175A (es) | 2010-08-02 |
KR20100096140A (ko) | 2010-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101888834A (zh) | 口服分散片 | |
JP5535616B2 (ja) | 口腔内崩壊錠剤のための直接圧縮性複合材 | |
JP4573397B2 (ja) | 速崩壊性固形製剤 | |
US20040265375A1 (en) | Orally disintegrating tablets | |
KR101565621B1 (ko) | 저치환도 히드록시프로필셀룰로오스 수분산액을 이용한 습식 조립 타정법 | |
JP4707073B2 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
WO2005037254A1 (ja) | 口腔内速崩壊性錠剤 | |
JP2001058944A (ja) | 速崩壊性固形製剤 | |
JP2009292843A (ja) | 固形製剤 | |
PT1145711E (pt) | Formulação de dosagem oral de dissolução instantânea | |
CN104244930A (zh) | 口腔崩解片及其制造方法 | |
JP7336388B2 (ja) | 錠剤及びその製造方法 | |
KR20090057241A (ko) | 구강내 붕괴정 및 그 제조법 | |
US20100092564A1 (en) | Composition of and Method for Preparing Orally Disintegrating Tablets | |
JP2008536922A (ja) | オランザピンの医薬用経口崩壊錠 | |
US20150272889A1 (en) | Orally Disintegrating Tablet | |
WO2013047353A1 (ja) | ヒドロキシアルキルセルロース微粒子を含有する口腔内崩壊錠 | |
JP2003034655A (ja) | 速崩壊性固形製剤 | |
ES2359377T3 (es) | Celulosa microcristalina coprocesada y alcohol de azúcar como excipiente para formulaciones de comprimidos. | |
CN102727456B (zh) | 药物口腔崩解片及其制备方法 | |
JP4965096B2 (ja) | 圧縮成型製剤 | |
JP4601271B2 (ja) | 圧縮成形製剤およびその製造方法 | |
JP2001342128A (ja) | 湿度に対して安定された硬度を有する口腔内崩壊錠 | |
Reshma et al. | Superdisintegrants and their inevitable role i n orodispersible tablet | |
CN102772455A (zh) | 一种沙棘黄酮分散片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1146387 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG Effective date: 20130322 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Berlin Applicant after: BAYER PHARMA AG Address before: Berlin Applicant before: Bayer Schering Pharma AG |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: BAYER SCHERING PHARMA AG TO: BAYER PHARMACEUTICALS AG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130322 Address after: German Monheim Applicant after: BAYER INTELLECTUAL PROPERTY GmbH Address before: Berlin Applicant before: BAYER PHARMA AG |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20101117 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1146387 Country of ref document: HK |